Table 2.
Outcomes with postoperative vaginal cuff brachytherapy alone.
| Authors/reference | Publication year | N | Treatment | Control/survival | Total pelvic recurrence (%)a | Vaginal recurrence alone (%) |
|---|---|---|---|---|---|---|
| Aalders et al. [2] | 1980 | 277 | 60 Gy at surface (LDR) | 5-y OS, 91% | 6.9b | |
| Sorbe and Smeds [15] | 1990 | 404 | Ranging from 4.5 Gy x 6 to 9 Gy x 4 at 1.0 cm | 5-y OS, 91.8% | 3.0 | 0.7 |
| Noyes et al. [16] | 1995 | 63 | 16.2 Gy x 2 ovoids at surface | Median f/u 1.6-y OS, 98.5% | 1.6 | 0 |
| Kloetzer at al. [17] | 1997 | 108 | 10 Gy x 4 to 0.5 cm or 1.0 cm | 3-y OS, 96% | 0 | 0 – 3.1 |
| Eltabbakh et al. [18] | 1997 | 332 | 30 Gy at 0.5 cm (LDR) | 5-y DFS, 98.9% | 0.6 | 0 |
| MacLeod et al. [19] | 1998 | 141 | 8.5 Gy x 4 at surface | 5-y OS, 86–94% | 0.7 | 1.4 |
| Weiss et al. [20] | 1998 | 122 | 7 Gy x 3 at surface | 5-y RFS, 86.8% | 4.1 | 1.6 |
| Chadha et al. [21] | 1999 | 38 | 7 Gy x 3 at 0.5 cm | 5-y OS, 93% | 0 | 0 |
| Petereit et al. [22] | 1999 | 191 | 16.2 Gy x 2 at surface of ovoids | 4-y OS, 95% | 0.5 | 0 |
| Anderson et al. [23] | 2000 | 102 | 5 Gy x 3 at 0.5 cm | 5-y OS, 84% | 2.0 | 1.0 |
| Horowitz et al. [24] | 2002 | 164 | 7 Gy x 3 at 0.5 cm | 5-y OS, 87% | 1.2 | 1.2 |
| Alektiar et al [25] | 2002 | 233 | 7 Gy x 3 at 0.5 cm | 5-y OS, 90% ≥ 60 yr, 99% < 60 yr |
1.7 | 1.3 |
| Jolly et al. [26] | 2005 | 50 | 5 Gy x 5 at 0.5 cm | 4-y OS, 97% | 2.0. | 2.0 |
| Alektiar et al. [27] | 2005 | 382 | 7 Gy x 3 at 0.5 cm | 5-y OS, 93% | 3.1 | 0.8 |
| Solhjem et al. [28] | 2005 | 100 | 7 Gy x 3 at 0.5–0.7 cm | 3-y OS, 97.9% | 0 | 0 |
| Atahan et al. [29] | 2008 | 128 | 5.5 Gy x 5 at 0.5 cm | 5-y OS, 96% | 1.6 | 0 |
| McCloskey et al. [30] | 2010 | 87 | 7 Gy x 3 at 0.5 cm (HDR) or 30 Gy at 0.5 cm (LDR) | 2.3 | 1.1 | |
| Nout et al. (PORTEC-2) [6] | 2010 | 213 | 7 Gy x 3 at 0.5 cm (HDR) or 30 Gy at 0.5 cm (LDR) | 5-y OS, 84.8% | 3.8 | 1.8 |
| Sorbe et al. [31] | 2012 | 263 | 3 Gy x 6 or 5.9 Gy x 3 at 0.5 cm (HDR) or 20 Gy at 0.5 cm (LDR) | 5-y OS, 90% | 2.3 | 0.7 |
| Diavolitsis et al. [32] | 2012 | 169 | 7 Gy x 3 or 5.5 Gy x 4 at 0.5 cm (HDR) or 70 Gy at ovoid surface (LDR) | 5-y OS, 95.5% | 2.4 | 0.6 |
| Eldredge-Hindy et al. [33] | 2014 | 31 | 7 Gy x 3 at 0.5 cm or 6 Gy x 5 at surface, at least proximal 4 cm length of vagina | 3-y OS, 83%, 3-y DFS, 79% | 3.2 | 3.2 |
| Paydar et al. [34] | 2015 | 22 | 42 Gy at 0.5 cm depth (HDR) or 65 Gy at surface (LDR) | 4.5 | 4.5 |
Gy = Gray, LDR = low dose rate, y = year, OS = overall survival, DFS = disease free survival, RFS = relapse-free survival, HDR = high dose rate,
a
Defined as pelvic alone and simultaneous pelvic plus vaginal; vaginal recurrences alone are not included.
b
Vaginal and pelvic combined, results not separated.